Venture capital investment in biopharmaceutical companies is booming in 2020. And while novel cancer and immuno-oncology programs continue to attract large sums, drug developers working on treatments for neurological diseases also are raising sizeable venture rounds. Among six companies with recently announced financings, Nura Bio Inc. launched with $73m in series A cash and Encoded Therapeutics Inc. closed a $135m series D round.
Pitchbook and the National Venture Capital Association (NVCA) reported in their Venture Monitor report earlier this month that biopharma companies raised $12bn in the first half, which at a pace of $6bn per quarter puts the industry on track to top 2019’s full-year total of $17bn as well as the record $19bn raised by drug developers in 2018
South San Francisco-based Nura Bio emerged on 29 July with a series A round led by The Column Group in a syndicate that also included Samsara BioCapital and Euclidean Capital